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RÉSUMÉ 
L’implication des cellules B dans le développement de l’auto-immunité ne cesse 
d’être illustrée par de récentes publications. Les cellules présentent des peptides 
du soi aux cellules T auto-réactives ce qui mène à la production de cytokines pro-
inflammatoires et d’anticorps auto-réactifs. Dans le présent document, nous 
explorons la présentation antigénique et la modification post-traductionnelle du 
complexe majeur d’histocompatibilité II (CMH-II). MARCH1 est une E3 ubiquitine 
ligase qui cible le CMH-II et le relocalise le complexe vers les endosomes de 
recyclage.  Ainsi, MARCH1 est un inhibiteur de la présentation d’antigènes 
exogènes. Ici, nous démontrons que MARCH1 est exprimé seulement dans la 
sous-population des cellules B folliculaires et que cette expression est perdue lors 
de l’entrée dans les centres germinatifs. Nous proposons que MARCH1 établie 
une barrière de formation de centres germinatifs. Nous démontrons le lien entre 
MARCH1 et la hausse de CMH-II à la surface des cellules B à la suite d’un 
traitement à l’IL-10. De plus, nous avons testé plusieurs stimuli activateurs des 
cellules B et démontrons que MARCH1 est régulé à la baisse dans tous les cas. De 
plus, nous mettons en valeurs le rôle de la voie canonique d’activation de NF-κB 
dans cette régulation de MARCH1. Finalement, nous avons développé un système 
de lentivirus exprimant MARCH1 qui nous permet de forcer l’expression de 
MARCH1 dans des cellules réfractaires à la transfection. Nous discutons de 
l’implication de cette régulation du CMH-II par MARCH1 dans le développement 
de maladies auto-immunes. 
 
 
 
 
Mots clés : CMH-II, MARCH1, Cellules B, Auto-immunité, présentation 
antigénique. 
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ABSTRACT 
Increasing evidence suggests a major role for B cells in the onset of auto-immune 
diseases. B cells present self-antigens to auto-reactive T cells which leads to the 
production of pro-inflammatory cytokines and auto-immune antibodies. Here we 
look at the process of antigen presentation and at post-transcriptional 
modifications of the MHC-II molecule. MARCH1 is an E3 ubiquitin ligase which 
targets MHC-II and re-localises the complex into recycling endosomes. Thus, 
MARCH1 is a direct inhibitor of exogenous antigen presentation. Here we show 
that only follicular B cells express MARCH1 and that upon germinal center entry, 
these cells lose all traces of MARCH1. We propose that MARCH1 may establish a 
threshold for germinal center creation. Moreover we demonstrate that the well-
established increase in surface MHC-II induced by IL-10 on murine B cells is a 
result of a decrease in MARCH1 expression. We tested different B cell activation 
stimuli and showed that upon activation, MARCH1 mRNA is decreased in a time-
dependent manner. In addition, we demonstrate the implication of the canonical 
NF-κB pathway in this regulation. Finally, we developed a lentiviral vector system 
expressing MARCH1 which enables us to force the expression of our target 
protein in non-transfectable cell types. We discuss the implication of MARCH1 in 
the presentation of self-antigens to auto-reactive T cells and the generation of 
auto-immunity. 
 
 
 
 
 
Key words: MHC-II, MARCH1, B cells, auto-immunity, antigenic presentation.  
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Il était une fois une cellule…
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CHAPTER 1 - LITERATURE REVIEW 
 
1.0 The Immune response 
To achieve a successful protection against invading pathogens of all sorts, a 
tightly regulated and coordinated response of the two branches of the immune 
response must be attained. The first obstacle against these attacks is known as 
the innate arm of the immune system and consists of mechanical barriers and 
non-specific cellular responses. In contrast, the second branch, the adaptive 
immune system, finds its meaning in multiple features such as specificity, 
memory and self-nonself discrimination. The development of the adaptive arm 
relies on the coordinated action of dendritic cells and B and T lymphocytes in 
response to antigenic stimulation. While dendritic cells are better antigen 
presenting cells than B cells or macrophages, their functions have been largely 
characterised in regard to MHC-II and antigen presentation. Here, we will try to 
bring some light onto the regulation of MHC-II molecules and some key related 
mechanisms in B cells. 
 
1.1 B lymphocytes 
 
1.1.1 Origin 
B cells originate from pluripotent haematopoietic stem cells (HSC)1. B cell 
development begins in the bone marrow with the differentiation of the HSC 
which leads to the generation of pre-pro-B cells. It’s in these cells that the Ig 
heavy chain gene rearrangement begins and then continues later in the pro-B 
cells. The intracellularly-expressed rearranged heavy chain is then expressed in 
large B cells along with surrogate light chain; together they form the pre-BCR that 
relocates to the cell surface1. The Ig light chain is then rearranged, in the small 
pre-B cells, which leads to the production of the mature BCR with unique 
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specificity. The first BCR is expressed as an IgM on the surface of immature cells2. 
Immature B cells then go through a first checkpoint at which self-reactive BCR-
expressing cells are removed before exiting the bone-marrow as transitional (T1) 
B-cells to migrate to the spleen. Once at destination, T1 B cells migrate to splenic 
follicles where they differentiate into non-circulating T2 B cells. The existence of a 
third transitional stage has been proposed but no functional role has been yet 
identified3. After all the transitional stages, B cells finally become long-lived 
mature cells. A model in which these cells form a follicular type I (FO I) population 
has been proposed (fig 1.1)4 but is not yet widely accepted. A binary cell fate then 
leads to the generation of, in most cases, FO II cells or, in fewer instances, 
marginal zone (MZ) precursor cells. While both sub-types possess different key 
functions discussed later, both populations are also distinct in their localisation 
within the spleen (fig 1.2). The differentiation fate is mostly regulated by the 
strength of the BCR signaling where a strong signal will favour a FO I fate and a 
weaker or absent BCR signal will stimulate a MZ fate (fig 1.3). In addition to the 
follicular and marginal zone B cells, a third mature B cell population has been 
discovered in mice. These B1 B cells seem to have a B220-CD19+ progenitor 
lineage that appears prior to pre-pro B cells, but intermediate stages have yet to 
be identified5  
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Figure 1.1. Murine B cell development. 
B-cells differentiate from haematopoietic stem cells (HSC) in the bone marrow 
and progress through several intermediate stages before egress into the 
peripheral circulation. Further maturation to follicular and MZ B-cells occurs in 
the spleen. B1 B-cells mature in the peritoneal cavity. The intermediate 
developmental stages currently defined are illustrated together with a list of 
important cell surface markers expressed at each stage (black text) and the status 
of Ig gene rearrangement (red text). Solid arrows indicate known pathways of 
differentiation. Dotted arrows indicate hypothetical pathways, which may contain 
undiscovered intermediates. MPP, multi-potent progenitor; LMPP, lymphoid-
primed multi-potent progenitor; CLP, common lymphoid progenitor; SLC, 
surrogate light chain. Figure and legend taken from Vaughan et al, 2011 
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1.1.2.0 Functions 
The first apparent role of B cells was observed in the 1960s when Max Cooper 
demonstrated that antibody production was completely abolished in chickens 
that were irradiated after the removal of their bursa of Fabricus (the primary site 
of B cell development in birds)6. Subsequently, the discovery of surface Ig on B 
cells as the B cell receptor (BCR) confirmed the one cell, one antibody model 
developed in the 1950s7. In the mid-1970s, it was fully accepted that B cells had a 
specific and unique way to recognize antigens and differentiate into antibody-
secreting plasma cells. Nowadays, several different subsets of B cells have been 
identified with distinct functions and responses. Here, we will not discuss 
plasmocytes or memory B cells since they have lost most of their antigen-
presenting functions and are of no importance to our current objectives. 
 
 
Figure 1.2. A schematic view of the anatomy of the spleen. 
This figure shows the location of the different mature B cell subsets within the 
spleen. Figure was taken from Pillai and Cariappa, 2009. 
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1.1.2.1 Follicular B cells 
Mature follicular B cells are responsible for the majority of T helper cell-
dependent humoral immune responses. Ultimately, these responses lead to 
immunological memory and generation of plasma cells8. During an infection, 
follicular B cells are able to recognize antigens through their surface BCR which 
will lead to the internalization, processing and presentation to CD4+ T cells of 
foreign antigenic particles. This interaction will in turn promote the rapid 
generation of plasma cells and to an eventual formation of germinal centers9. 
Somatic recombination will then take place in these micro environments and will 
lead to an increased affinity of the BCRs to antigens and subsequent isotype class 
switching8. Affinity-matured, isotype-switched B cells will differentiate into 
memory cells or long lived plasma cells that will migrate into the bone marrow. 
Memory B cells remain in peripheral lymphoid organs for whole life of the host. 
These cells will respond at a great speed to future microbial challenges10. 
 
1.1.2.2 Marginal zone B cells 
This population is exclusively found within the splenic marginal sinus and was 
initially thought to be specialized in a rapid T cell-independent antigen response. 
Within 3 days of an antigen encounter, such as bacterial capsular 
polysaccharides, MZ B cells can differentiate into antigen-specific plasma cells11. 
Since they respond so rapidly to blood-borne antigens, MZ B cells embody an 
innate immunity player. On the other hand, experiments in mice have shown that 
the marginal sinus is also composed of memory B cells, suggesting a long-lived 
immune response characteristic of the adaptive immune system12. Thus, MZ B 
cells are believed to be the main source of naturally occurring antibodies. While 
follicular B cells may present antigens to activated CD4+ T cells, they lack the 
ability to efficiently prime naïve T cells. On the other hand, MZ B cells have higher 
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levels of MHC-II and B7 proteins which makes them far more potent activators of 
naïve CD4+ T cells both in vitro and in vivo13. 
 
Figure 1.3. Marginal versus follicular fate. 
T2 immature B cells will either become marginal zone or follicular B cells 
following BCR engagement with self-antigen. A strong BCR signal will favour a 
follicular fate whereas a weak “tickling” of the BCR will favour a marginal zone 
fate. Figure was taken from Pillai and Cariappa, 2009. 
 
1.1.2.3 B1 B cells 
While the functions of MZ and FO B cells have been widely studied, B1 B cells 
have been identified fairly recently and thus, our knowledge of this population is 
quite restricted. For what is known, B1 B cells are associated with the humoral 
branch of the immune system and they dominate the peritoneal cavity in mice. 
They constitutively differentiate into plasma cells in the absence of antigen and 
secrete low-affinity IgM antibodies. CD5+ B1a B cells are responsible for the 
production of these natural antibodies which grant a non-specific response to 
invading pathogens prior to the mobilisation of adaptive immunity14. Moreover, 
this production of IgM is increased by Toll-like-receptor agonists such as LPS and 
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CpG15. On the other hand, CD5- B1b B cells are only mild producers of natural 
antibodies but, in contrast, they yield specific antibodies to T cell-independent 
antigens (TI-2) present in the peritoneal cavity. These antigens are able, by 
activating B cells, to mount an immune response without the help of T cells. This 
singularity also occurs with MZ B cells in the spleen but, additionally, B1b B cells 
confer long-lasting T cell-independent immunity16. In humans, CD5 is not 
confined to a single cell type, singling out this marker as an unreliable B1a B cell 
identifier. However, CD5+ B cells capable of secreting poly-reactive antibodies in 
vitro have been observed and might represent the human equivalent of the 
murine B1 b cells14. 
 
1.1.3 Pathology 
B cells are implicated in many pathologies, most notably lymphomas17 and auto-
immune disorders18. Auto-immune diseases are characterized by loss of 
peripheral tolerance and inappropriate production of autoantibodies. Many of 
the 80 distinct auto-immune disorders are associated with the development of 
autoantibodies12. Moreover, activated B cells secrete a variety of pro-
inflammatory cytokines and chemokines such as IL-6, TNF-α, IFN-γ, IL-12 and MIF, 
all of which are implicated in the inflammatory cascade of auto-immune 
pathologies. In addition, antigen presentation by auto-reactive B-cells is pivotal in 
several auto-immune disorders such as systemic lupus erythematosus and 
rheumatoid arthritis, and can stimulate autoimmunity independently of antibody 
production19. There is also increasing evidence that B cells can produce the 
potentially anti-inflammatory cytokine IL-10 and produce regulatory IgM 
antibodies that bind apoptotic cells which can block the inflammatory responses 
of macrophages and dendritic cells20. Moreover, memory B cells are also a pool of 
auto-reactive B cells which can promote and sustain the chronic ongoing of auto-
immune diseases. Having said all that, it becomes obvious that in order to 
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effectively fight auto-immune disorders, we must undertake an in-depth 
examination of B cell regulation mechanisms and functions. Here, we will 
principally look at mechanisms implicated in the presentation of self-antigens by 
B cells. 
 
1.1.4 B cell and transplantation 
Graft-versus-host disease (GVHD) is a major cause of morbidity and mortality 
after allogeneic stem cell transplantation19. Increasing evidence indicates that B 
cells might play a major role in certain pathologies and that depletion of these 
cells in patients could be a therapeutic avenue of choice20. Although the precise 
mechanisms of action of B cells in graft-versus-host rejection are still unknown, it 
is thought that a variety of effector pathways including antigen presentation, 
dysregulated auto-immune antibody synthesis or allogeneic antibody induction, 
might be implicated21. Recent findings suggest that B cells regulate antigen 
presenting functions previously allocated to other professional APCs during the 
initial response to alloantigen, highlighting the regulatory, antibody-independent 
role played by B cells during this response22, 23. 
 
1.1.5 Rituximab 
While more and more evidence strengthens the idea that B cells have a much 
more critical role than previously expected in many diseases, this notion first 
started to emerge many years ago. In the early 1990s a new treatment focusing 
on destroying over-reactive or dysfunctional B cells entered phase 1. This 
treatment, which is still in use today, consists of an anti-CD20 antibody which 
targets only B cells. While plasma cells do not generally express CD20 and thus 
cannot be targeted by the anti-CD20 antibody Rituximab, promising results have 
been obtained in the treatment of auto-immune diseases using this strategy. 
Some patients have shown extended period of remission without any decrease in 
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serum immunoglobulin, underlying an antibody-independent mechanism for 
Rituxumab24. Most notably, Rituximab targets auto-reactive B cells which results 
is lesser pro-inflammatory cytokine production, reduced depletion of healthy 
cells, and presentation of self-antigens to auto-reactive T cells25, 26. Moreover, 
recent studies using Rituximab include treatments for rheumatoid arthritis27, 
systemic lupus erythematosus, Sjögren’s syndrome, vasculitis, multiple sclerosis, 
Graves’ disease, idiopathic thrombocytopenia, dermatomyosis, polymyositis, 
pemphigus and bullous pemphigoid28. This new avenue of B cell-specific 
treatment is still in an early stage and many groups are currently making 
observations that certain B cell populations such as MZ, B1 and germinal center 
cells are more resistant to depletion by the anti-CD20 antibody29, 30  . Thus, new 
treatments are being developed to target other cell specific markers such as 
CD22, CD19, CD40-CD40L, BAFF and APRIL31. We believe that by understanding 
the functional mechanisms in B cells responsible for these pathologies, we might 
not require such a drastic treatment. By focusing on key events in the onset of 
auto-immune disorders we may be able to figure how to keep the auto-reactive B 
cells in check and avoid auto-immunity. 
 
1.2 B cell activation 
Resting B cells have very low antigen-presenting capacities and do not produce 
large amounts of cytokines. In order for B cells to become potent players in the 
host response against infections, they need to be activated through specific 
signaling pathways, some of which include T cell surface molecules, antigens, 
cytokines and bacterial products. Here, we are focusing on the antigen-
presenting functions of B cells, which mainly take place following activation and 
thus, relevant activating mechanisms will be discussed. 
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1.2.1 B cell receptor 
The basis of antigen recognition by B-cells resides in their specific clonal receptor. 
The BCR is composed of a membrane-bound immunoglobulin and a di-sulfide-
linked heterodimer composed of Igα and Igβ32, 33. In the absence of antigen, each 
host generates a pool of B-cells in which each cell expresses a single heavy and 
light chain gene, the product of somatic recombinations34. The net result of gene 
rearrangement is a possibility of well over 1010 different immunoglobulin 
molecules and thus a virtually infinite number of antigens recognized. Self-
reactive B-cells are removed from the repertoire while the BCRs with the highest 
affinity are selected upon antigen recognition. Membrane-bound 
immunoglobulins have a very short cytoplasmic tail ranging from only three to 28 
amino acids35. While these chains are too short to associate with intracellular 
signaling molecules, the Igα and Igβ possess cytoplasmic tails of 61 and 48 amino 
acids respectively within which is comprised a conserved immuno-receptor 
tyrosine-based activation motif (ITAM)36. Antigen binding induces BCR 
aggregation and phosphorylation of its ITAM motifs by Src family 
phosphotyrosine kinases (PTK) such as Lyn, Fyn, Blk or Lck37. The phosphorylated 
ITAM recruits Syk (Spleen tyrosine kinase) through its SH2 domain which leads to 
an amplification of ITAM phosphorylation and the triggering of at least four 
different signaling cascades with downstream effectors such as p38 MAPK, 
JNK1/2, ERK1/2, NF-κB, CaMK and NFAT (fig 1.4)38.  These molecular events are 
also implicated in the fate-determining steps of immature B cells. Strong BCR 
signal, coming from stringent association of self-antigens to the receptor, induce 
the differentiation of immature B cells to follicular B cells. On the other hand, if 
the BCR signal strength is weak, immature B cells will become marginal zone B 
cells. This dichotomy is of utmost importance to us as the BCR signal strength will 
dictate the phenotypic differences between these two populations. 
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Figure 1.4. BCR downstream transduction pathways. 
Figure was taken from Monroe. J. G. 2006 
 
1.2.2 Toll-like receptors 
B cells are a key link between the adaptive and innate immunity as they both 
express antigen-specific BCRs and various TLRs. These TLRs are pattern-
recognition receptors (PRRs) that recognize conserved bacterial products 
including bacterial lipopolysaccharides (TLR4), flagellin (TLR5), lipopeptides 
(TLR2), double-stranded RNA (TLR3), single-stranded RNA (TLR7/8) and CpG-
containing DNA (TLR9)39, 40. For all the TLRs, except TLR3, early signal transduction 
occurs through MyD88 and IRAK, while later responses include NF- κB, IL-6, TNF-α 
and IL-12 (fig 1.5). B cell activation, proliferation and class-switching are all 
influenced by TLR pathways41. For instance, TLR7 was shown to induce IgM and 
IgG secretion in both naïve and memory human B cells42 and several TLR agonists 
increase MHC-II, CD80 and CD86 surface expression in different B cell subsets43. 
While TLR agonists have been extensively studied in regard to their activating 
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properties, they have been shown to assist, rather than induce, proliferation of 
certain sub-types of B cells such as memory B cells44. For instance, immature B 
cells poorly proliferate upon LPS stimulation even though they express 
considerable amounts of TLR445. Moreover, it has been shown, that in the 
context of infection, TLR4 and TLR2 agonist readily reach the bone-marrow and 
inhibit lymphoid precursor proliferation46. In addition, our results along with 
others, demonstrate that a TLR4 engagement promotes the generation of CD23+ 
transitional B cells derived from splenocytes in vitro47. These results suggest that 
TLRs can shape certain maturation pathways as opposed to their classical 
activating role. Finally, LPS, a TLR4 ligand, has the potential to activate and 
dramatically induce antigen presentation in B cells and thus, will be discussed 
here. 
 
Figure 1.5. TLR4 downstream transduction pathways. 
Figure taken from Ragnardòttir et al. 2011 
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1.2.3 CD40-CD40L interaction 
B cells constitutively express at their surface the CD40 antigen, a member of the 
nerve growth factor/tumor necrosis factor receptor family48. This receptor plays a 
crucial role in B cell activation, T cell-dependent antigen-driven isotype switching 
and germinal center formation. CD40 interacts with its ligand, CD40L (CD154), 
present mostly on activated CD4+ T cells, which stimulates B cells to deliver 
activating signals to T cells. Besides B and T cells, CD40 and/or CD154 are also 
expressed by many cell lineages including dendritic cells, 
monocytes/macrophages, endothelial cells, epithelial cells and fibroblasts as well 
as platelets49. Six TRAF proteins (TRAF1-6) have been described so far, and all of 
them, except TRAF4, can interact, directly or indirectly, with CD4050. Signaling 
downstream of CD40 is dependent on the presence of adaptor proteins which are 
recruited to the cytoplasmic domain of CD40. Of these, NF-κB, the mitogen-
activated protein kinases (MAPKs – p38 and JNK) as well as the phophoinositide 
3-kinase (PI3K) have been shown to be modulated by TRAFs recruitment (fig 1.6). 
Moreover, CD40 can directly recruit Jak3 and induce its activation, which leads to 
the phosphorylation and signal transduction of STAT550. Thus, transduction 
pathways following CD40-CD40L interaction have the potential to influence many 
different cellular outcomes such as proliferation, differentiation, activation, 
immunoglobulin secretion, cell survival and antigen presentation. 
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Figure 1.6. CD40 downstream transduction pathways. 
Figure taken from Chen et al. 2006. 
1.2.4 IL-10 
IL-10 was first described more than 20 years ago as cytokine synthesis inhibitory 
factor (CSIF), a cytokine, produced by Th2 clones, which could inhibit the 
production of IL-2, IL-3, lymphotoxin (LT)/TNF, IFN-γ, and granulocyte-
macrophage CSF (GM-CSF), by Th1 cells51. Nowadays, the cellular sources of IL-10 
have been extended to almost all leukocytes even though the most potent 
producers of in vivo IL-10 are monocytes, macrophages and T-helper cells52. The 
activity of IL-10 on Th1 cells was found to be indirect, acting on antigen-
presenting cells’ (APC) activating properties, mainly through the modulation of 
costimulatory molecules (B7; CD80/CD86), MHC-II expression and IL-12 
production53,54. The biological effects of IL-10 are so incredibly heterogeneous 
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and numerous that they can hardly be generalised to a few key functions. Indeed, 
chip analyses have shown that IL-10 was responsible for the up-regulation of 
about 1600 genes and the down-regulation of about 1300 other genes mainly 
through the activation of STAT3 (fig 1.7)55. This cytokine partially inhibits the 
activity of induction of other cytokines such as IFN-γ, IL-2, TNF-α, and IL-4. Not 
only does IL-10 affect APCs’ activities and T cell responses, but it also enhances 
the survival of B cells and tumour cells56, 57. Paradoxically, it has been shown to 
induce apoptosis in certain types of cancers such as chronic B cell leukemia58. 
One of the first studies performed on IL-10 focused on the activation properties 
of this cytokine, showing that IL-10 increased surface expression of MHC-II and 
viability of murine splenic B cells59. These results, along with more recent work 
showing that IL-10 decreases MHC-II surface expression in monocytes and 
dendritic cells, allow us to appreciate the complex control and timing implicated 
in IL-10 signaling. This cytokine is usually produced after the pro-inflammatory 
mediators such as IFN-γ and TNF-α. Thus, it has a role in limiting and preventing 
an excessive immune response and in limiting collateral damage60. Little work has 
been done on the B cell response to IL-10 and the relatively late activation 
mechanisms of these cells occurring following the inflammation process.  
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Figure 1.7. IL-10 downstream transduction pathways. 
Figure taken from Sabat et al. 2007 
 
 
1.3 Antigenic presentation 
Many times above we referred to antigenic presentation as the key feature of 
this work. Here we will describe the different players and properties of this 
phenomenon.  We will focus on the major-histocompatibility complex (MHC) 
proteins, their structure and functions.  
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1.3.1 HLA genes 
As opposed to the B-cell receptors and antibodies, the T-cell receptors can only 
recognize antigens that have been processed and presented by the major 
histocompatibility complex (MHC). This complex is a collection of genes located 
on chromosome 6 in humans where it is known as the HLA complex (fig 1.8), and 
chromosome 17 in mice where it is known as the H-2 locus61. In both cases, the 
MHC genes are organized in different regions encoding three major classes of 
molecules.   
 
The class I genes encode for the α chain of the MHC-I molecules HLA-A, HLA-B 
and HLA-C which are referred to as the classical class I molecules. On the other 
hand, the β2-microglobulin chain is encoded in a “non-HLA” region located on 
chromosome 15. The MHC-I molecules are responsible for antigenic presentation 
of endogenous peptides and are thus implicated in the presentation of antigens 
to CD8+ cytotoxic T cells. As such, the MHC-I molecules are expressed on all 
nucleated cells. 
 
The class II genes encode for the α and β chains of the classical molecules HLA-
DP, HLA-DQ and HLA-DR and the heterodimers of the non-classical molecules 
HLA-DM and HLA-DO62. The MHC-II heterodimers are responsible for the 
presentation of exogenous peptides and are thus implicated in the presentation 
of antigens to CD4+ helper T cells. As such, the MHC-II molecules are mainly 
expressed on antigen-presenting cells (APC) such as B-cells, dendritic cells, 
monocytes and macrophages. 
 
The class III genes encode some proteins implicated in the immune response but 
not directly in antigen presentation. Such products include proteins from the 
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complement system (C4, C2 and factor B) and several inflammatory cytokines 
including the tumour necrosis factor (TNF). 
 
 
Figure 1.8. The human HLA complex genes. 
The complex is conventionally divided into three regions on chromosome 6: I, II, 
and III. Each region contains numerous genes, only some of which are shown. Of 
the class I and II genes, only the expressed genes are depicted. Figure was taken 
from Klein et al, 2000. 
 
1.3.2 Major histocompatibility complex I (MHC-I) 
The MHC-I complex is formed by the non-covalent association of an alpha chain, 
containing three domains, α1, α2 and α3, and by a β2-microglobulin (fig 1.9). The 
association of the two chains forms a complex expressed constitutively at the 
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surface of virtually all nucleated cells63. This complex is formed in the 
endoplasmic reticulum, where an endogenous peptide enters the peptide groove 
of the heterodimer. The MHC-I-peptide complex then migrates to the surface of 
the plasma membrane where it presents its antigen to CD8+ cytotoxic T cells. In 
this work, we will not focus on MHC-I because of the nature of the presented 
peptide. MHC-I presents endogenous peptides to T cells, and thus healthy cells 
will be ignored while cells presenting foreign peptides will be destroyed. Here, we 
are interested in the antigenic presentation of exogenous peptides associated to 
MHC-II complexes on the surface of professional APCs. 
 
1.3.3 Major histocompatibility complex II (MHC-II) 
The MHC-II heterodimers are highly polymorphic trans-membrane glycoproteins. 
They are formed through the non-covalent association of an α (32 to 34 kDa) and 
β chain (29 to 32 kDa) (fig 1.9). Three different isotypes of the MHC-II molecules 
can be found in humans, HLA-DP, HLA- DQ and HLA-DR, while in the mouse, only 
two are present, I-A and I-E. These complexes are mainly expressed on 
professional APCs but can also be found on thymic epithelial cells62. Moreover, 
interferon-gamma can induce the expression of these molecules in a wide range 
of cell types. This induction is controlled through the expression of the class-II 
trans-activator CIITA64. Because of the ability of the MHC-II complex to present 
exogenous peptides and thus raise an immune response against invading 
pathogens and the fact that the antigenic presentation through MHC-II can be 
regulated through many different pathways, this thesis will focus on the post-
transcriptional modifications of MHC-II and the ramifications on B cell activation 
of such modifications. 
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Figure 1.9.  MHC-I and MHC-II structure. 
Figure was taken from Klein et al., 2000. 
 
1.3.3.1 Classical and non-classical molecules 
The MHC-II molecules are divided into two groups; the classical and the non-
classical molecules. The human classical MHC-II comprises the HLA-DP, -DQ and –
DR heterodimers while the murine counterpart has only two, H2-A and –E. MHC-
II proteins are characterised by their extremely high levels of polymorphism 
which is vital to their antigen presentation function. 
 
The non-classical molecules, on the other hand, are more conserved than MHC-II 
and comprise the HLA-DM and –DO heterodimers in humans65. In the mouse, 
these molecules are known as H2-DM and –DO. While these molecules cannot 
harbour a peptide in their groove and thus present antigens, their role relies in 
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controlling the function of the MHC-II complex. HLA-DM is responsible for the 
removal of the invariant chain peptide (CLIP) located in the MHC-II groove. 
Moreover, HLA-DM can edit the peptide repertoire by facilitating the binding of 
higher affinity peptides to the MHC-II groove66, 67, 68.  On the other hand, HLA-DO 
is known for its inhibitory effect on HLA-DM. HLA-DO thus reduces the removal of 
the CLIP peptide and impairs the loading of endogenous peptides69  It is thus 
implicated in the editing of the peptide repertoire and can, in this fashion, reduce 
the ability to raise an immune response through its impairment of antigenic 
presentation. Moreover, HLA-DO can restrict certain peptides from entering the 
MHC-II groove by selecting for peptides bigger than 18kDa70   
 
1.3.4 MHC-II structure 
The classical heterodimer is sub-divided into 4 distinct domains, the peptide 
groove, an immunoglobulin-like domain, a trans-membrane region and a 
cytoplasmic tail71. The peptide groove is formed from the interaction of the α1 
and β1 domains and contains 8 β sheets and 2 α helices equally distributed 
among both domains. This groove allows binding of an 8 to 12 amino acid 
antigenic peptide which will eventually be presented to CD4+ T cells72, 73. The 
hyper-polymorphic residues of the MHC-II complex are located in this groove and 
allow a wide range of peptides to bind through hydrogen bonds formed between 
the groove and the antigenic peptide amino acids74. 
 
The next domain comprises the α2 and β2 regions of each chain. These regions 
are more conserved and possess a structure analogous to immunoglobulins. The 
interaction between MHC-II and the CD4 receptor occurs through these regions75. 
The trans-membrane domain anchors the complex in the lipid bi-layer of the 
plasma membrane. Thus, these trans-membranes are highly enriched in 
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hydrophobic residues. It has been shown that the β chain trans-membrane could 
be implicated in the signal transduction required for B cell activation76. 
 
The cytoplasmic domains are composed of hydrophilic residues and act as an 
intracellular endosome trafficking motif77, 78, 79. They also contain critical residues 
for cyto-skeleton interaction80. Moreover, many functional analyses demonstrate 
the implication of the cytoplasmic tails in the intracellular signaling upon 
activation of B cells81, 82. Finally, it has been shown that the cytoplasmic domains 
of MHC-II can be ubiquitinated, leading to an internalization and degradation of 
the complex and thus, reduction in antigenic presentation83. 
 
1.4 Ubiquitination 
Ubiquitination plays a central role in many different cellular processes. Much like 
phosphorylation, ubiquitination is a reversible covalent modification that 
modulates the stability, activity and localization of target molecules. It has been 
associated with ubiquitin-mediated proteasome degradation, but also with 
sorting of proteins along the endocytic pathway into lysosomes84, 85. 
Ubiquitination is the result of the concerted effort of three enzymes, an 
ubiquitin-activating E1 (E1) enzyme, an ubiquitin-conjugating E2 (E2) enzyme and 
an ubiquitin-ligase E3 (E3) enzyme (fig1.10a). The E1 activates, in an ATP-
dependent manner, ubiquitin molecules which are subsequently transferred to 
an E2. An E2-E3 complex is then formed and the nature and localization of this 
complex will determine the substrate specificity. Finally, the ubiquitin moiety is 
transferred to the target substrate and the E2-E3 complex is dissociated, allowing 
for a new round of ubiquitination86. Typically, ubiquitin molecules are transferred 
on lysines, but serines, methionines, cysteines and threonines have been found 
to be suitable, but less efficient, ubiquitin acceptors87, 88. The ubiquitin molecule 
contains seven lysines which can themselves be ubiquitinated, forming poly-
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ubiquitin chains. It is believed that poly-ubiquitin chains linked through lysine at 
position 48 of ubiquitin (Lys 48) target protein substrates for degradation by the 
proteasome, whereas poly-ubiquitin chains of alternative linkages (such as Lys 
63) carry out signaling functions independent of proteolysis (fig1.10b)89. 
Substrates can thus be mono-ubiquitinated, one ubiquitin on one lysine, multi-
ubiquitinated, one ubiquitin on many lysines, or poly-ubiquitinated. These 
different target modifications can lead to fates such as lysosomal or proteosomal 
degradation, recycling, relocalisation or even a change in function90. 
 
 
Figure 1.10.The ubiquitination process 
A. The different steps involved in ubiquitination from the E1 enzyme to the E3 
and substrate. B. The different types of ubiquitination. Figure was taken from 
Woelk et al. 2007. 
 
1.5 MARCHs 
There are two main families of E3 ubiquitin ligases, HECT- and RING- containing 
domains91. The MARCH family of E3 ligases is characterised by the presence of an  
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N-terminal RING-finger (Cys3HisCys4; C3HC4)92, 93. Moreover, the MARCH family 
contains 11 known members which target molecules implicated in the immune 
response92. Until recently, no mechanism had been described to explain the 
retention of MHC-II molecules inside immature DCs. Two separate studies have 
shown that I-A dimers are ubiquitinated and relocated into endocytic 
compartments94, 95. Once activated by LPS, I-A molecules are no longer 
ubiquitinated and are thus stabilized at the cell surface. Recently, two other 
papers have shown that two RING-CH E3 ligases, MARCH1 and -8, can 
ubiquitinate mouse MHC II molecules in B lymphocytes and DCs, respectively94, 96. 
The human orthologs had already been shown to down-regulate the TfR, Fas and 
CD8697. MARCH8 is ubiquitously expressed and would play a general role in the 
endocytic pathway. M1 mRNA is found principally in secondary lymphoid organs, 
a distribution consistent with a role in immunity. Dr. Thibodeau’s laboratory has 
previously shown that IL-10 induced the up-regulation of MARCH1 in human 
primary monocytes which led to the ubiquitination and subsequent intracellular 
retention of the MHC-II surface molecules98.  
 
1.6 Lentiviruses as a gene delivery system 
Modern experiments on specific proteins often make use of over-expression 
systems to clearly delineate the role of these target proteins. While over-
expressing a gene may not precisely represent constitutive amounts found in 
normal cells, these systems represent a useful tool for characterizing specific 
players in complex cellular pathways. 
 
Prior to the use of lentiviral vectors, onco-retroviruses, such as the murine 
leukemia virus (MLV), had been characterised as excellent gene delivery tools. 
First, they possess a large cloning capacity of up to 10kbs. Second, retroviral 
vectors stably integrate their cargo into the chromosome of the target cell. Third, 
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they do not transfer viral genes enabling the transduced cells to avoid virus-
specific cytotoxic T lymphocyte-mediated destruction99. Retroviral vectors are a 
powerful tool for gene transfer, but they lack a critical attribute of lentiviral 
vectors; the ability to transduce non-dividing cells. Moreover, most of the 
potential targets for gene therapy include neurons, hepatocytes, myocytes and 
hematopoietic stem cells99, 100, 101, all of which are non-dividing cells. As such, 
lentiviral vectors were first developed to target CNS cells102 in neurodegenerative 
disorders research, i.e. Parkinson’s disease. The first generations of lentiviral 
vectors developed were produced by expressing as much as 8 viral genes into 
producer HEK293T cells103. Possible recombination of these viral genes and 
production of a replication competent virus was soon established as a health 
hazard. The current, third-generation, lentiviral vectors are produced by 
expressing only the viral genes Gag, Pol and Rev. Additionally, the lentiviruses are 
pseudotyped with the vesicular stomatitis virus (VSV) G envelope protein to 
enhance its tropism103. Moreover, to decrease the chance of recombination and 
dramatically increase the safety issues of lentiviral vectors, four different 
plasmids are used to express all the genes required for viral assembly. Typically, a 
first vector will encode for Gag and Pol, a second for Rev, a third for the VSV-G 
gene and a fourth for the gene to be delivered. The four vectors are co-
transfected into HEK293T cells and the lentiviral vectors are harvested from the 
supernatant two to three days post-transfection.  
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1.7 Hypotheses and objectives 
As increasing evidence suggests that B cells might play a major role in the 
development and intensity of auto-immune diseases, it is of the utmost 
importance to recognise and characterise the multiple mechanisms associated 
with these diseases. Auto-reactive B cells produce pro-inflammatory cytokines 
and present self-antigens to auto-reactive T cells. Dr. Thibodeau’s team has 
previously shown that MARCH1 is a key immune suppressor which could 
counteract auto-immune pathologies. 
 
Hypothesis 1 
MARCH1 is a negative regulator of autoimmunity in antigen presenting cells, and 
thus in B cells, MARCH1 is tightly regulated. 
 
Objective 1 
We aim to characterise the different populations of B cells in regard to MARCH1 
expression. 
 
Hypothesis 2 
Upon activation, MARCH1 is decreased to allow maximal antigenic presentation 
and thus efficient T cell priming. 
 
Objective 2 
We will assess the regulatory patterns of MARCH1 following the activation of B 
cells and try to uncover the regulatory mechanisms involved. 
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Recent evidence suggests that intracellular MHC-II molecules promote Toll-like-
receptor signaling by forming a complex with CD40 and Btk. 
 
Hypothesis 3 
MARCH1, by relocating surface-associated MHC-II molecules to endosomes, 
increases Toll-like-receptor signaling by increasing the formation of MHC-CD40-
Btk complexes. 
 
Objective 3 
We will assess the inflammatory cytokine production pattern of B cells in the 
presence or absence of MARCH1, MHC-II and Btk. 
 
Hypothesis 4 
Lentiviruses expressing MARCH1 DNA should be able to transfer the gene and 
lead to the expression of the MARCH1 protein in non-transfectable cells. 
 
Objective 4 
We will try to develop a lentiviral vector system which would allow us to 
transduce cells with the MARCH1 gene leading to its expression and activity in 
target cells. 
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CHAPTER 2 – MATERIALS AND METHODS 
 
2.1 Lentiviral vector production 
Production of third-generation lentiviral vectors pseudotyped with the vesicular 
stomatitis virus (VSV) G envelope protein was achieved by transient co-
transfection of four plasmids in Lenti-XTM 293T cells (Clontech). The packaging 
constructs used were pLP1 and pLP2 (Invitrogen), which encode the HIV-1-
derived Gag/Pol and Rev genes respectively. The VSV-G protein was expressed 
from pLP/VSVG (Invitrogen) and GFP or GFP-mM1 from the expression plasmid 
pLVX-Tet-On Advanced (Clontech). After transient transfection of the four 
plasmids by polyethyleneimine (PEI, Polyscience Inc.) in Lenti-XTM 293T cells, the 
cells were incubated at 37°C in DMEM medium (supplemented with 5% serum) 
for 48 hours.  The supernatant was harvested and filtered through a 0,4μm low-
protein-binding membrane filter, concentrated by ultracentrifugation at 85000g 
for 105 minutes and re-suspended in serum-free DMEM. Viral stocks were stored 
at -80°C and titers and activity were determined by transduction and flow 
cytometry analysis of GFP and MHC-II expression in 293E-CIITA cells. 
 
2.2 Transduction 
Adherent cells were transduced in 6-well plates by removing the existing media, 
adding the lentiviral vectors directly onto the cells, adjusting the volume to 250μL 
with DMEM medium and then incubating at 37°C in the presence of 8μg/mL of 
Polybrene (Sigma) for one hour. DMEM medium was then added to a final 
volume of 2mL supplemented with 4μg/mL of Polybrene (Sigma) and then 
incubated for 48 hours at 37°C. Cells were then washed with PBS and analysed for 
GFP and MHC-II expression by flow cytometry analysis. Non-adherent cells were 
transduced in the same fashion but were previously centrifuged to remove the 
existing medium. 
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2.3 Chemical compounds and cytokines 
The following compounds were used: polyethyleimine 2.5kD linear from 
Polysciences Inc., and Polybrene from Sigma, which was used at a final 
concentration of 4 or 8μg/mL. STAT3 inhibitor: STATTIC was used at a final 
concentration of 10µM. NF-kB inhibitor: BAY-11-7082 was used at a final 
concentration of 25µM unless otherwise indicated. JNK inhibitor: SP600125 was 
used at a final concentration of 5µM. ERK1/2 inhibitor: PD98,059 was used at a 
final concentration of 5µM. p38 inhibitor SB239063 was used at a final 
concentration of 2.5µM. Human IL-10 was purchased from Sigma and was used at 
a final concentration of 40ng/mL. LPS was purchased from Sigma and used at a 
final concentration of 100ng/mL. 
 
2.4 Plasmids 
The lentiviral vectors pLP1, pLP2 and pLP/VSGS were purchased from Invitrogen. 
The expression plasmid pLVX-Tet-On advanced was purchased from Clontech. 
The murine MARCH1 cDNA was kindly provided by Satoshi Ishido and was cloned 
and YFP-tagged into the pcDNA3.1 vector obtained from Daniel Lamarre. This was 
done using the PCR-overlapping method and the BAMH1 and Xho1 restriction 
enzymes. The pLVX constructs were sub-cloned from the pcDNA3.1-YFP-mM1 
newly made construct by an Xba1 digestion and ligation. 
 
2.5 Cell culture and transfections 
The Lenti-XTM 293T cells purchased from Clontech and the 293E CIITA cells were 
cultured in DMEM (Wisent) supplemented with 5% FBS (Wisent). For lentiviral 
vector production, 5M Lenti-XTM 293T cells were plated in 10cm Petri dishes 24 
hours prior transfection. They were transfected using 3μg of polyethylneimine 
(PEI) per μg of DNA. For the 293E CIITA, 0,25M cells were plated in 6-well plates 
24 hours prior transduction and titration. 
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2.6 Mice and immunizations 
C57BL/6 (B6) mice were purchased from Charles River Laboratory. Use of animals 
was in accordance with University of Montreal’s Institutional Animal Care and 
Use Committee guidelines. Age- and sex-matched 6 to 10 week old B6 mice were 
immunized intra-peritoneally with 50 μg of (4-hydroxy-3-nitrophenyl)acetyl (NP) 
conjugated to chicken γ globulin (CGG) (Biosearch Technologies) precipitated in 
alum (Pierce) and 14 days later germinal center B cells were isolated from the 
spleen and were analyzed by FACS and quantitative real-time PCR. 
 
2.7 Antibodies 
Anti-mouse antibodies used for FACS analysis and cell sorting and purchased from 
BD Pharmingen (unless otherwise noted) were as follows: FITC-conjugated anti-I-
Ab (M5/114; ATCC), anti-CD93 (C1qRp; AA4.1), anti-T and B cell activation Antigen 
(GL7/Ly-77; GL7); PE-conjugated anti-CD95 (Fas/APO-1; Jo2), anti-IgM (μ), anti-
CD21/CD35 (CR2/CR1; 7G6); PE/Cy7-conjugated anti-CD23 (B3B4) and Alexa fluor 
647-conjugated anti-CD19 (6D5; eBioscience). 
 
2.8 Real-time quantitative PCR 
Cells were re-suspended in TRIzol (Sigma) and frozen at -20 until RNA isolation. 
Per 1mL of TRIzol, 250μL of chloroform was added. Samples were incubated at 
room temperature for 5 minutes and centrifuged at 13000g for 15 minutes at 
4°C. The aqueous phase was collected and 700μL of isopropanol was added per 
1mL of TRIzol. Samples were incubated at room temperature for 10 minutes and 
then centrifuged at 13000g for 15 minutes at 4°C. The DNA/RNA pellet was 
washed with 70% ethanol and air dried. DNA digestion was performed as per the 
manufacturer’s protocol (Ambion). RNA quantification was obtained using a 
Nanodrop. cDNA was generated using SuperscriptTM reverse transcriptase as per 
the manufacturer’s instruction (Invitrogen) from 1μg of RNA per reaction. Each 
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qPCR reaction contained 1,5μL of 5μM of each primer (table 1), 1μL of cDNA, 
8,5μL of DEPC water and 12,5μL of SYBR Green mix (Roche) for a final volume of 
25μL. Each sample was run in duplicate and a no-template control without cDNA 
(NTC) was run for every primer set. 
 
Table 1. Sequence of primer sets used in figures 3.1, 3.2, 3.4 and 3.5. 
 
2.9 Statistical analyses 
A two-tailed, paired Student’s t test was used to determine statistically 
significant differences among groups for all figures (where mentioned) but 
3.1 where a two-way ANOVA using the Bonferroni method was used to 
determine statistically significant differences between FO B cells and other 
groups. 
 
 
 
 
 
 
 
 
 
 
 
 
Target Forward Primer sequence Reverse Primer sequence 
TNF-α 5’ GTGATCGGTCCCCAAAGG 3’ 5’ GGGTCTGGGCCATAGAACTG 3’ 
IL-6 5’TGAAGTTCCTCTCTGCAAGAGACT 3’ 5’ TAGGGAAGGCCGTGGTTGT 3’ 
MARCH1 5’ CCTTGCGCTTTGTCCACCAGTCCT 3’ 5’ AATATTTTCCTCCTTTCGCTCGTG 3’ 
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CHAPTER 3 – RESULTS 
 
MARCH1 is only expressed in follicular B cells 
Throughout their maturation, B cells express a wide range of different molecules 
that dictate their phenotype and function. It had previously been shown94 that 
immature and marginal zone B cells do not express MARCH1 as opposed to 
follicular B cells. Here, to follow MARCH1 regulation, we widened the search and 
included precursors and different specialized B cell stages such as germinal 
center, plasma and bone-marrow cells. 
 
  
 
 
 
 
 
 
Figure 3.1. MARCH1 is only expressed in follicular B cells 
qPCR analysis was performed on different B cell populations that were sorted by flow 
cytometry. Cells sorting was performed as follow: T1: CD19+, AA4.1+, IgM Hi, CD23- ; 
T2: CD19+, AA4.1+, IgM Hi, CD23+ ; MZ: CD19+, AA4.1-, CD21 Int-Hi, CD23 low-Int; 
FO: CD19+, AA4.1-, CD21 Int, CD23 Int; GC: CD19+, GL7+, FAS+; Plasma cells: 
CD138+ ; Bone-Marrow: CD19+. Error bars represent the SEM between three 
independent experiments. P-value was obtained by comparing the difference 
between FO B cells and the other cell populations. 
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We isolated the different sub-populations (at least 95% purity) from mice spleens 
or bone marrow using specific cell-surface-expressed molecules and flow 
cytometry cell-sorting. Quantitative real-time qPCR was then used to evaluate the 
mRNA expression of MARCH1. While we confirm that T1, T2 and marginal zone B 
cells do not express MARCH1, we also show that germinal center, plasma and 
bone-marrow B cells are also devoid of MARCH1 mRNA (Fig 3.1). Thus, follicular B 
cells represent the only B cell sub-population that expresses MARCH1.  
 
MARCH1 is down-regulated upon B cell activation 
Upon activation, B cells transit from a resting to an effector state. Activated B 
cells have increased antigen presenting functions, phagocytosis and cytokine 
production capacities105. Moreover, these cells can undergo differentiation to 
further increase their specificity and ability to counteract infections, i.e. 
plasmocyte or memory cell differentiation. A wide panel of stimuli can induce B 
cell activation such as LPS, CD40L-CD40 interaction, BCR engagement and IL-10. 
Since MARCH1 dampens antigen presenting functions of APCs, we set out to 
investigate whether activation of B cells was related in any way to MARCH1 
expression. Accordingly, we treated mice splenocytes with activating agents (LPS, 
CD40L) and evaluated the amplitude of MARCH1 mRNA expression using 
quantitative real-time PCR (fig 3.2a). We are not able to detect MARCH1 at the 
protein level because of its constitutively low expression. We show that upon 
activation by LPS or CD40L-CD40 interaction, B cells decrease their expression of 
MARCH1 mRNA in a time-dependent fashion. LPS down-modulates MARCH1 for 
the first 8 hours and then, the mRNA level gradually increases until at least 24 
hours post-stimulation (fig3.2a left panel). On the other hand, CD40L-CD40 
interaction progressively decreases MARCH1 expression in a time dependent 
manner for at least 24 hours (fig3.2a right panel). 
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Dr. Thibodeau’s laboratory has previously shown that MARCH1 can be induced by 
IL-10 in monocytes, leading to a decreased MHC-II surface expression98. Others 
have shown that IL-10 treatment leads to an increase in MHC-II surface 
expression in B cells94. To clarify these contradictory results, we used flow 
cytometry to investigate the surface expression of MHC-II in mouse splenocytes 
after 12 hours of an IL-10 or LPS treatment (fig 3.2b). Then, we used the 
corresponding samples along with quantitative real-time PCR, to evaluate the 
amount of MARCH1 mRNA (fig 3.2c). LPS was used as a control for down-
modulation of MARCH1 mRNA level. We show that IL-10 decreases MARCH1 
mRNA expression but less effectively than LPS. Also, we correspondingly 
correlated this effect with an increase in the surface expression of MHC-II on B 
cells.  
 
While LPS has been shown to induce the transcription of MHC-II expression, IL-10 
has not been proved able of a similar effect. To elucidate the role of MARCH1 in 
the modulation of surface MHC-II, we finally tested the hypothesis that if the 
increase in MHC-II surface expression was MARCH1 dependent, follicular B cells 
would be the only population to manifest an effect after IL-10 treatment as they 
are the only B cells to express MARCH1. We separated follicular B cells from the 
remaining splenic B cells and treated the two groups with either IL-10 or LPS and 
measured the surface expression of MHC-II using flow cytometry. We show that 
while LPS increases MHC-II levels in both groups, IL-10 was only able to do so in 
follicular B cells, suggesting that MARCH1 was the key player in this MHC-II 
modulation (fig 3.2d). Thus, IL-10 and LPS decrease MARCH1 expression which 
leads to an increase in MHC-II surface expression. 
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                   D. 
 
 
 
 
 
 
 
Figure 3.2 MARCH1 mRNA is down-regulated upon activation of B cells 
A. Quantitative real-time PCR analysis of MARCH1 expression at different time 
points after either LPS treatment or CD40L-CD40 interaction. Expression is 
illustrated as fold level of non-treated samples at time 0. B. Quantitative real-
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time PCR analysis of MARCH1 expression at 12h after treatment of either IL-10 or 
LPS. C. Histogram of flow cytometry analysis showing the surface expression of 
MHC-II for the corresponding samples (fig 3.2c). Population was gated on CD19+ 
cells. D. Mean-fluorescence values of a flow cytometry analysis showing the 
MHC-II surface expression at 12h after treatment of either IL-10 or LPS on 
follicular B cells and follicular-deprived B cells. Error bars for A and B represent 
the SEM between three independent experiments. Experiments shown in C and D 
are representative of four replicates. For this figure, the p-values are 
represented as follow: p≤0,001 = ***, p≤0,002 = ** and p≤0,05 = *. 
 
FO-devoid XID mice do not up-regulate MHC-II upon IL-10 treatment 
XID mice have a mutation in the Bruton’s tyrosine kinase gene (Btk), and are a 
model of human X-linked immunodeficiency. They have a B cell specific defect 
which results in a dramatic decrease in follicular B cell numbers. We hypothesised 
that FO-devoid XID mice splenocytes may not respond to IL-10 stimulation in 
regard to surface MHC-II levels. To test this premise, we treated either C57BL/6 
or XID splenocytes with IL-10 or LPS for 12 hours and assessed the surface 
expression of MHC-II by flow cytometry. Our results indicate that even though 
XID splenocytes respond normally to LPS stimulation, they display no increase in 
MHC-II surface expression after IL-10 treatment (fig 3.3). Thus, these results 
demonstrate that IL-10 increases MHC-II surface expression only in follicular B 
cells. 
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A.                                                                            B. 
Figure 3.3 IL-10 has no effect on MHC-II surface expression in FO-devoid XID 
splenocytes. 
C57BL/6 (in A) or XID (in B) splenocytes were harvested and treated for 12 hours 
with either LPS or IL-10. Flow cytometry was then used to assess the amount of 
surface MHC-II proteins in all samples. Numbers represent the mean-
fluorescence intensity of MHC-II surface expression. Results shown are 
representative of three different experiments. NS represents the auto-
fluorescence of non-stained cells. 
 
The LPS-mediated down-modulation of MARCH1 is NF-κB dependent 
Activation of B cells can lead to a wide range of functions such as immunoglobulin 
production and secretion, cytokine production, maturation, differentiation, 
migration and effector functions. Major signaling pathways implicated in the 
activation of B cells through TLR4 or CD40 stimulation include the 
phosphorylation or activation of JNK, ERK1/2, p38, NF-κB and STAT346, 47. To 
investigate the role of each of these downstream effectors on MARCH1 
expression, we treated splenocytes for 2 hours with specific inhibitors and then 
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with LPS for 4 hours. We then used quantitative real-time PCR to estimate the 
amount of MARCH1 mRNA in each sample. We show that while the inhibitors for 
JNK, ERK1/2 and p38 have no effect on the down-modulation of MARCH1 by LPS, 
those specific for STAT3 and NF-κB impaired, and even increase, in the case of NF-
κB, the expression of MARCH1 (Fig3.4a). These results indicate that the activation 
of NF-κB and STAT3 is probably responsible for the down-regulation of MARCH1 
mRNA by LPS. We then performed a dose-response analysis to confirm our 
results on NF-κB since it presented the most notable effect. We treated mice 
splenocytes with 3 different doses of the NF-κB inhibitor for 2 hours and then 
either treated or not with LPS for 4 hours. Finally, we used quantitative real-time 
PCR to evaluate the level of synthesis of MARCH1 mRNA. Here, we show that the 
NF-κB inhibitor hinders, in a dose-dependent manner, the LPS-driven down-
regulation of MARCH1 (fig 3.4b). 
 
        A.                                                                 B. 
 
Figure 3.4 The LPS-driven down-modulation of MARCH1 is NF-κB dependent  
A.  Mice splenocytes were treated with inhibitors of STAT3, NF-κB, JNK, ERK1/2 or 
p38 (inhibitor is indicated in parenthesis) for 2 hours and then treated with LPS 
for 4 hours. Quantitative real-time PCR were performed on each sample to  
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evaluate the amount of MARCH1 mRNA. B. Mice splenocytes were treated with 
different concentration of the NF-κB inhibitor for 2 hours and then treated or not 
with LPS. Quantitative real-time PCR were performed on each sample to evaluate 
the amount of MARCH1 mRNA. Error bars represent the SEM between four 
independent experiments. 
 
MARCH1 could increase the LPS response and B cell activation 
Recent evidence by the group of Liu et al. has demonstrated a role for MHC-II in 
TLR signaling. Intracellular, but not membrane-associated, MHC-II molecules 
interact with the Btk tyrosine kinase through the costimulatory molecule CD40. 
Then, the activated Btk interacts with Myd88 and TRIF and thus promotes TLR 
signaling. Thibodeau et al. have previously shown that MARCH1 ubiquitinated 
membrane-bound MHC-II molecules leading to their intracellular relocalisation 
and degradation98. Moreover, the group of Toyomoto et al. have shown that 
MARCH8, an analogue of MARCH1, transgene impaired LPS-driven production of 
TNF-α and IL-6 in mice PBMC. We treated C57BL/6, Ii-KO and XID mice with LPS 
for 24 hours and used quantitative real-time PCR to evaluate the amount of TNF-
α and IL-6 synthesis (Fig 3.5a). We show that while TNF-α production is 
dramatically impaired in Ii-KO and XID mice, only XID mice have reduced IL-6 
production following LPS treatment.  Ii-KO mice have reduced amounts of MHC-II 
proteins and virtually absent follicular B cells pools while XID mice have a 
mutated Btk protein and dramatically reduced follicular B cell pools. Moreover, 
both mice have reduced MARCH1 expression as seen by quantitative real-time 
PCR (fig 3.5b). 
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Figure 3.5. Impaired TLR signaling in follicular B cells/MARCH1 deficient mice. 
A.  C57BL/6, Ii-KO or XID mice splenocytes were treated with LPS for 24 hours. 
Quantitative real-time PCR was then used to assess the amount of TNF-α or IL-6 
mRNA. B. C57BL/6, Ii-KO or XID mice splenocytes were treated with LPS for 24 
hours. Quantitative real-time PCR was then used to assess the amount of 
MARCH1 mRNA. Amount of mRNA is shown as fold of non-stimulated cells mRNA 
levels and error bars represent the SEM of 4 independent experiments. 
  
A. 
B. 
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Lentiviral vectors expressing MARCH1 DNA can infect non-dividing cells. 
Expression of foreign genes in eukaryotic cells can be achieved through many 
different techniques including electroporation, transfection and transduction.  
 
Figure 3.6. Transduction of HEK293-CIITA cells with a lentiviral vector expressing 
the MARCH1 gene. 
Cells were transduced as described previously in Materials and Methods. 
Different volumes of viral stock were used to determine the titer of the stock. 
Percentage of YFP-positive cells was determined by flow cytometry for each 
volume. Titer was established at 3x107 infectious particles per mL. The figure also 
demonstrates the down-regulation of surface MHC-II molecules in a dose 
dependent manner when adding MARCH1-expressing lentiviruses. Results shown 
are representative of at least 4 different experiments. 
YFP 
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While not every cell type can be efficiently electroporated or transfected, 
transduction using viral vectors widens the possibilities. For instance, the tropism 
of the transducing particles can be enhanced using VSV-G proteins. Moreover, 
lentiviruses have been shown to proficiently transfer their DNA cargo into non-
dividing cell types such as neurons and dendritic cells. Bearing this in mind, we 
developed a lentiviral system encoding the YFP-tagged MARCH1 gene to 
ultimately force its expression in non-transfectable primary B cells. We 
transduced HEK293 cells stably expressing the class II trans-activator CIITA with 
different volumes of a viral stock which enabled us to determine our stock titer to 
3x107 infectious particles per mL. Our preliminary results using these viruses 
indicate that MARCH1 can be expressed in almost 100% of the infected cells 
while maintaining viability. Moreover, MARCH1 is functionally expressed in 
HEK293 CIITA cells and its presence can be followed by a YFP tag as well as a 
decrease in amounts of surface MHC-II molecules (fig 3.6).  
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CHAPTER 4 - DISCUSSION 
 
MARCH1 is an important regulator of antigenic presentation in certain APCs. In 
addition to targeting surface-bound MHC-II molecules, MARCH1 also regulates 
the surface expression of various molecules, including CD86 and TfR97. Bearing 
this in mind, we set out to understand the different mechanisms and patterns of 
MARCH1 expression in particular subsets of APCs. We decided to look at the 
mouse system since human splenocytes are not readily available. Moreover, our 
results, along with those of others, indicate that there are some critical 
differences between the mouse and the human system regarding the 
responsiveness of B cells to specific stimuli. For instance, human B cells do not 
up-regulate surface MHC-II expression in response to IL-10. Increasing evidence 
suggests a major role for B cells in auto-immune diseases due to their vast array 
of immune functions such as antigenic presentation, self-reactivity and secretion 
of pro-inflammatory cytokines. Thus, we directed our initial research towards the 
regulation and function of MARCH1 in B cells, seeking a link between the tightly 
regulated modulators of immune functions and self-reactivity leading to auto-
immune diseases. 
 
While MARCH1 targets proteins implicated in antigenic presentation of 
exogenous peptides, it is not present in all professional APCs. For instance, 
MARCH1 in present in immature dendritic cells following treatment with IL-10 but 
is virtually absent in macrophages94. Moreover, the group of Matsuki published a 
study showing that MARCH1 was also absent in T cells while being highly 
expressed in splenic B cells and more specifically in follicular B cells94. We further 
challenged these findings by characterizing the different stages of B cell 
maturation from the bone-marrow to highly specialised populations. Here we 
showed that follicular B cells are the only sub-population of B cells that expresses 
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MARCH1. Moreover, follicular B cells entering germinal centers lost all traces of 
MARCH1 mRNA. While these results are in accordance with the work of Matsuki, 
they emphasise the fact that the expression of MARCH1 is restricted in the 
majority of B cell subtypes. A question rises as to why only follicular B cells have 
constitutively high amounts of MARCH1 mRNA. A rational starting point for this 
inquiry resides in the fate determination of immature B cells, differentiating into 
either marginal zone or follicular B cells. A strong BCR signal to self-antigens is 
required for the generation of follicular B cells as opposed to a weak “tickling” of 
the BCR for proper marginal zone B cell formation105. Antigens of a higher affinity 
presumably below the threshold required for deletion, receptor editing or the 
induction of anergy, might direct the development of follicular B cells. Thus, FO B 
cells, if left unchecked, might present self-antigens, that bind their BCR with high 
affinity, to CD4+ T cells leading to auto-reactivity. We believe that an increase in 
MARCH1 in this population might be the result of a controlled antigen 
presentation mechanism meant to prevent auto-immunity. MARCH1 would be 
induced, leading to a decrease of membrane-associated MHC-II and CD86 
proteins ensuing in an impaired or reduced presentation of self-antigens. We will 
pursue this inquiry using the MARCH1-KO mice. Paradoxically, these mice do not 
show symptoms of auto-immunity. We believe that the role of MARCH1 cannot 
be fully characterised in immune systems that have not been previously primed. 
For instance, what would happen if we were to induce EAE in MARCH1-KO mice? 
Would these mice show exacerbated symptoms due to increased presentation 
and processing of self-antigens? Thus, we will challenge MARCH1-KO mice with 
different inducers of auto-immunity and assess the development of disease to try 
and isolate the role of MARCH1. 
 
Another interesting finding is that germinal center B cells do not express MARCH1 
mRNA. Follicular B cells internalize antigens through their BCR and subsequently 
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present these MHC-II-associated antigens to a sub-population of T cells known as 
CD4+ follicular helper T cells (TFH). The interaction between B and T cells is 
required for entry into germinal centers, thus a constant low amount of antigenic 
presentation is required for GC entry. The effectiveness of GC creation by 
individual B cells is dependent upon help provided by TFH cells and antigen 
presentation by these B cells. As shown by the group of Draghi, germinal center 
entry by B cells can be modulated by antigen presentation players. They elegantly 
demonstrated that H2-O, a biochemical inhibitor of peptide loading onto MHC-II, 
acted as a repressor of GC entry, thus, highlighting the importance of antigen 
presentation for this selective process. Moreover they showed that upon entry 
into germinal centers, B cells significantly decrease their amount of H2-O 
proteins. We hypothesized that MARCH1, because of its ability to modulate 
antigen presentation, and making a parallel with H2-O, could act as a germinal 
center guardian. MARCH1-expressing follicular B cells have reduced antigen 
presenting abilities and thus are restrained from GC entry. H2-O indirectly selects 
for higher affinity peptides to be presented and thus creates a selective pressure 
for specific antigens to be mounted on MHC-II in order for B cells to enter GCs. 
While H2-O modulates the quality of presented peptides, MARCH1 is a non-
qualitative antigen presentation repressor. MARCH1 relocates MHC-II molecules, 
disregarding its antigen load, leading to the accumulation and degradation of the 
MHC-II-peptide complex in recycling endosomes. Thus, only highly responsive 
follicular B cells that previously increased their MHC-II pool may effectively prime 
TFH cells and eventually take place in the germinal center reaction. These results 
suggest that MARCH1 may set a threshold for germinal center entry in the spleen 
by selecting B cell clones that have optimal antigen presenting abilities. As such, if 
we were to immunise a mouse with HEL peptides, only B cells that possess BCRs 
that strongly associate with HEL residues will have the possibility to enter GCs. 
Moreover, B cells that were able to adequately stimulate T cells with sufficient 
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amounts of MHC-II-HEL complexes will bypass the regulation by MARCH1 and go 
on to enter GCs.  
 
It is generally accepted that there are two main signals required for proper T cell 
activation. The first is believed to be the interaction between the T cell receptor 
(TCR) and MHC-antigen complex on the surface of antigen-presenting cells. The 
second signal comes from costimulatory molecules such as CD80 and CD86 on the 
surface of APCs which interact with CD28 on the surface of T cells. Resting B cells 
do not express high levels of MHC-II nor costimulatory molecules. Activating 
agents such as TLR agonists, CD40L and IL-10 have been found to up-regulate 
surface MHC-II, CD80 and CD86 in mice. It is thus believed that certain stimuli are 
necessary prior to T cell engagement to increase, to an acceptable amount, the 
machinery needed for successful antigen presentation. Since MARCH1 was found 
to target MHC-II and CD86, we investigated its regulation in response to 
activating stimuli. We found that all of the tested stimuli, LPS, CD40L and IL-10, 
decreased the MARCH1 mRNA amounts significantly in B cells. This down-
regulation of MARCH1 also corresponded with an increase in surface expression 
of MHC-II. We believe that these results suggest a probable link, through 
MARCH1, between B cell-activating stimuli and increased antigen presentation 
potential.  
 
Since follicular B cells represent the only sub-type of B cells that express 
MARCH1, we repeated our experiments in this population using LPS or IL-10. We 
found that while LPS increased MHC-II surface expression in FO and in non-FO B 
cells, IL-10 only increased MHC-II in FO B cells. These results suggest that the 
increase in MHC-II surface expression following IL-10 treatment takes place only 
in FO B cells due to a decrease in MARCH1 expression. Moreover, it has been 
shown that IL-10 was not able to increase surface expression of MHC-II in X 
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chromosome-linked immunodeficiency (XID) mice. These mice carry a mutation 
on their Btk gene which leads to major defects in B cell maturation resulting in a 
drastic depletion of follicular B cells. Thus, we conclude that IL-10 has no effect 
on B cells from XID mice because they lack FO B cells, the sole sub-type to express 
MARCH1.   
 
We believe that while IL-10 has immuno-suppressive functions on other APCs and 
on Th1 cells, IL-10 also possesses immuno-stimulatory properties on B cells. In the 
case of an auto-immune disease, IL-10 has been proposed to have a role as a 
peripheral tolerance establisher by suppressing the production of pro-
inflammatory cytokines by Th1 clones and reducing presentation of self-antigens 
by immature DCs53, 59. Here we propose that IL-10, by decreasing MARCH1 
expression in B cells, helps to raise a Th2 cell response, which would in turn 
reduce or control auto-immune reactions. Moreover, dendritic cells represent the 
most potent cell type to present antigens, thus being the best at presenting self-
antigens. We believe that during auto-immunity, IL-10 suppresses DCs’ ability to 
present antigens while increasing B cells’ capability. B cells are less efficient APCs 
than DCs and thus can be used when antigen presentation should be limited to 
raising the lowest level of immunity. Interestingly, the group of Lesage (REF) 
recently highlighted the potentially stimulatory role of IL-10 on B cells. They have 
shown that CD4-CD8- “double negative “(DN) T cells have the ability to lyse B cells 
loaded with self-antigens through MHC-II recognition. As such, IL-10, which 
increases surface MHC-II, may increase the DN-T cell-driven apoptosis of B cells.  
Moreover, IL-10 induces apoptosis in DN-T cells which could in turn stimulate B 
cells for proliferation and indirectly protect against DN-T cells. Since follicular B 
cells are the main circulatory B cell subset, we can hypothesise that MARCH1 is 
overexpressed in these cells to protect against DN-T cell-driven lysis. When IL-10 
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is produced and most DN-T cells are cleared, MARCH1 is down-modulated in B 
cells, allowing a full expression of surface MHC-II molecules. 
 
During our analyses of MARCH1 regulation, we tested different stimuli that all 
decreased MARCH1 expression in B cells. While they do not affect MARCH1 to the 
same extent, similarities were observed. For instance, the downstream pathways 
implicated in TLR4 and CD40 signaling both exploit the same key components, 
namely NF-κB, STAT3, JNK1/2, ERK1/2 and p38. Thus we tested every single 
effector in the down-regulation of MARCH1 through TLR4 or CD40 ligation. We 
found that NF-κB and, to a lesser extent, STAT3 were probably responsible for the 
down-regulation of MARCH1. We also demonstrated a dose response effect of 
the canonical NF-κB pathway inhibitor BAY11-7082. These results are interesting 
considering the NF-kB activation taking place downstream of the BCR which leads 
to the generation of MARCH1+ follicular B cells. It has been shown that FO B cells, 
at resting state, already contain in their nucleus, high amounts of p50 homo-
dimers106. Upon TLR engagement for instance, p50/c-Rel and p50/p65 hetero-
dimers rapidly relocate from the cytoplasm to the nucleus leading to MARCH1 
down-regulation. We hypothesise that the hetero-dimers, upon entry in the 
nucleus, dislocate the p50 homo-dimers turning off MARCH1 induction. Future 
experiments must include analyses of nucleus versus cytoplasm composition of 
NF-kB subunits as well as the characterisation of the MARCH1 promoter. 
 
A key component of innate immunity resides in the ability to recognize antigens 
in a non-specific manner. Such interaction takes place via pattern-recognition 
receptors including Toll-like receptors. New evidences suggest a non-classical role 
for MHC-II molecules in TLR signaling107. After recognition of their ligand, TLR4, 
TLR3 and TLR9 induce the association of intracellular MHC-II with Btk through 
CD40. This complex increases the responsiveness to further TLR signaling by 
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keeping Btk in an activated state. This was interesting to us as only intracellular 
MHC-II molecules were able to create this complex and strengthen TLR signaling. 
We hypothesised that MARCH1 played a key function in the cascade because it 
induces the relocalisation of membrane-bound MHC-II to recycling endosomes. 
Thus MARCH1 would increase TLR signaling through the relocalisation of MHC-II. 
We started our study by using either invariant chain-knockout (Ii-KO) mice that 
have reduced amounts of MHC-II molecules and abrogated follicular B cell 
populations. As these mice represent a useful tool in understanding the role of 
MHC-II in TLR signaling, we treated their splenic B cells with LPS and looked at the 
expression of TNF-α and IL-6. Our results show that while IL-6 mRNA was not 
altered in Ii-KO mice, TNF-α mRNA amounts were dramatically impaired in these 
mice. These experiments suggest that intermediate amounts of MHC-II molecules 
can be sufficient for LPS-induced TNF-α production. Also, these results highlight 
the different mechanisms taking place downstream of TLR4. Thus, while both 
TNF-α and IL-6 are produced following TLR4 engagement in B cells, they are 
differentially controlled in regard with MHC-II signaling. Moreover, we tested XID 
mice which have a point mutation in their Btk gene leading to compromised B cell 
development and virtually absent follicular B cell populations. In these mice, TNF-
α and IL-6 production are both dramatically reduced following LPS treatments. 
While an easy way to analyse these data is to look at the Btk mutation and a dys-
regulation of the whole system, here we will propose an alternative view. We 
believe that the nearly depleted follicular B cells expressing MARCH1 are lacking, 
and thus, most of the MHC-II molecules are located at the cell surface, incapable 
of associating with CD40 and Btk. It is obvious that mutated Btk proteins are 
probably mainly responsible for the decreased cytokine production in XID mice, 
but we believe that MARCH1 is of key value in this pathway. We will further 
investigate this issue using the MARCH1 KO mice. Results were obtained by 
another group using these mice and they found that bone-marrow-derived 
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macrophages and DCs transduced with MARCH8, an analogue of MARCH1, had 
decreased TNF-α and IL-6 production108. Moreover, they found the effect to be 
post-transcriptional as the mRNA was not affected. In the near future, we hope to 
show that MARCH1-KO B cells have decreased mRNA levels of TNF-α and IL-6. We 
believe that, while analogues, MARCH8 and MARCH1 have different targets, one 
of which would be implicated in TLR signaling. On the other hand, this target 
would not be affected by MARCH1. 
 
With these findings, we believe we can make a strong case concerning the 
implication of MARCH1 in auto-immunity onset. While MARCH1 had already been 
characterised as a repressor of MHC-II-antigen presentation, here we present 
evidence concerning the regulation of MARCH1 in B cells. Moreover, we propose, 
that because of its expression in B cells and its tight regulation, MARCH1 may play 
a key role in the development of auto-immunity. Activated B cells have decreased 
MARCH1 amounts which in turn lead to an increase presentation of self-antigens. 
In addition, we believe that MARCH1 can increase TLR signalling by increasing the 
intracellular pool of MHC-II molecules. Ultimately, the presence of MARCH1 in B 
cells may heighten the threshold of activity necessary to induce auto-immunity. 
 
Finally, we developed a lentiviral system able to transfer the MARCH1 gene and 
lead to its expressing and the subsequent down-regulation of surface MHC-II 
molecules. This tool will prove of value to study the role of MARCH1 in non 
transfectable cells such as B cells. Moreover, we believe that the forced 
expression of MARCH1 could allow us to identify new interacting partners in cells 
that previously had too low amounts of MARCH1 proteins. Lastly, by increasing 
MARCH1’s expression, we might be able to control the aberrant presentation of 
self-antigens without depleting crucial cell populations and, because of 
MARCH1’s specificity, without disrupting key pathway.  
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CHAPTER 5 - CONCLUSION 
 
We set out to characterise the expression of MARCH1 in different B cell subsets 
and to understand its regulation following the activation of B cells. We found that 
MARCH1 was highly expressed in a specific sub-type of mature B cells, namely 
follicular B cells. Moreover, we demonstrated that, upon activation of B cells, 
MARCH1 was down-modulated which leads to an increase in the amounts of 
surface MHC-II molecules. We are the first to characterise this phenomenon and 
highlight the role of MARCH1 following an IL-10 treatment. We believe that our 
findings may be part of the increasing pool of results suggesting a paradoxal role 
of IL-10. In one instance, IL-10 can stimulate B cells but serve as an immune 
suppressor in other cell types. While our results do not answer semantic 
questions about the uncommon role of IL-10 in B cells, we believe that our 
findings pave the way for key discoveries in the field of auto-immunity. 
 
Moreover, we proposed a role for MARCH1 in TLR signalling. New evidence 
suggests an implication of intracellular MHC-II which could be translated to a 
functional role MARCH1. We believe that these results might complement recent 
findings on the highly regulated TLR signalling pathways. Finally, we developed a 
lentiviral system to force the expression of MARCH in multiple refractory cell 
types. Overall, the results provided in this work describe a new mechanism 
implicated in B cell activation and strengthen our understanding of the complex 
regulatory properties of IL-10. Moreover, we provide a new tool for future 
experiments. 
 
  
53 
 
CHAPTER 6 - REFERENCES 
 
1. Hardy RR, Hayakawa K. B cell development pathways. Annu Rev Immunol. 
2001;19:595–621. 
 
2. Vaughan AT, Roghanian A, Cragg MS. B cells—Masters of the immunoverse. Int 
J Biochem Cell Biol. 2011;43:280-5 
 
3. Allman D, Pillai S. Peripheral B cell subsets. Curr Opin Immunol. 2008;20:149–
57. 
 
4. Cariappa A, Boboila C, Moran ST, Liu H, Shi HN, Pillai S. The recirculating B cell 
pool contains two functionally distinct, long-lived, post-transitional, follicular B 
cell populations. J Immunol. 2007;179:2270–81. 
 
5. Dorshkind K, Montecino-Rodriguez, E. Fetal B cell lymphopoiesis and the 
emergence of B-1-cell potential. Nat Rev Immunol. 2007;7:213–219. 
 
6. LeBien TW, Tedder TF. B lymphocytes: how they develop and function. Blood. 
2008;112:1570–80. 
 
7. Nossal GJ. One cell, one antibody: prelude and aftermath. Immunol Rev. 
2002;185:15–23. 
 
8. McHeyzer-Williams LJ, McHeyzer-Williams MG. Antigen-specific memory B cell 
development. Annu Rev Immunol. 2005;23:487–513. 
 
54 
 
9. MacLennan IC, Toellner KM, Cunningham AF, Serre K, Sze DM, Zuniga E, et al. 
Extrafollicular antibody responses. Immunol Rev. 2003;194:8–18. 
 
10. Tarlinton D. B-cell memory: are subsets necessary? Nat Rev Immunol. 
2006;6:785–90. 
 
11. Vinuesa CG, Sze DM, Cook MC, Toellner KM, Klaus GG, Ball J, et al. 
Recirculating and germinal center B cells differentiate into cells responsive to 
polysaccharide antigens. Eur J Immunol. 2003;33:297–305. 
 
12. Vinuesa CG, Sanz I, Cook MC. Dys-regulation of germinal centers in auto-
immune disease. Nat Rev Immunol. 2009;9:845–57. 
 
13. Attanavanich K, Kearney JF. Marginal zones, but not follicular B cells, are 
potent activators of naive CD4 T cells. J. Immunol. 2004;172:803–11. 
 
14. R. Berland and H.H. Worti. Origins and functions of B-1 cells with notes on the 
role of CD5. Annu Rev Immunol. 2002;20: 253–300. 
 
15. Y.S. Choi and N. Baumgarth. Dual role for B-1a cells in immunity to influenza 
virus infection. J Exp Med. 2008;205:3053–3064. 
 
16. K.R. Alugupalli, J.M. Leong, R.T. Woodland, M. Muramatsu, T. Honjo and R.M. 
Gerstein. B1b lymphocytes confer T cell-independent long-lasting immunity. 
Immunity. 2004;21:379–390. 
 
17. Stevenson GT, Cragg MS. Molecular markers of B-cell lymphoma. Semin 
Cancer Biol. 1999;9:139–47. 
55 
 
18. Dörner, T., Jacobi, A., M., and Lipsky, P., E. B cells in autoimmunity. Arthritis 
Research & Therapy. 2009;11:247 
 
19. Shimabukuro-Vornhagen A, Hallek MJ, Storb RF, von Bergwelt-Baildon MS. 
The role of B cells in the pathogenesis of graft-versus-host disease. Blood. 
2009;114:4919–27. 
 
20. Bartok B, Silverman GJ. Development of anti-CD20 therapy for multiple 
sclerosis. Exp Cell Res. 2011;15;1312-8 
 
21. Cutler C, Miklos D, Kim HT, Treister N, Woo SB, Bienfang D, et al. Rituximab 
for steroid-refractory chronic graft-versus-host disease. Blood. 2006;108:756–62. 
 
22. Noorchashm H, Greeley SA, Naji A. The role of T/B lymphocyte collaboration 
in the regulation of auto-immune and alloimmune responses. Immunol Res. 
2003;27:443–50.  
 
23. Liu C, Noorchashm H, Sutter JA, Naji M, Prak EL, Boyer J, et al. B lymphocyte-
directed immunotherapy promotes long-term islet allograft survival in nonhuman 
primates. Nat Med. 2007;13:1295–8. 
 
24. I. Sanz, J.H. Anolik and R.J. Looney. B cell depletion therapy in auto-immune 
diseases. Front Biosci. 2007;12:2546–2567. 
 
25. G.J. Silverman and D.A. Carson. Roles of B cells in rheumatoid arthritis, 
Arthritis Res Ther. 2003;5;4:S1–S6. 
 
56 
 
26. J.C. Edwards, L. Szczepanski, J. Szechinski, A. Filipowicz-Sosnowska, P. Emery 
and D.R. Close et al. Efficacy of B-cell-targeted therapy with rituximab in patients 
with rheumatoid arthritis. N Engl J Med. 2004;350:2572–2581. 
 
27. M.C. Levesque, Translational mini-review series on B cell-directed therapies: 
recent advances in B cell-directed biological therapies for auto-immune disorders. 
Clin Exp Immunol. 2009;157:198-208. 
 
28. Uchida, Y. Hamaguchi, J.A. Oliver, J.V. Ravetch, J.C. Poe and K.M. Haas et 
al.The innate mononuclear phagocyte network depletes B lymphocytes through 
Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J 
Exp Med. 2004;199:1659–1669. 
 
29. C. Mauri and M.R. Ehrenstein. The ‘short’ history of regulatory B cells. Trends 
Immunol. 2008;29:34–40. 
 
30. M.C. Levesque. Translational mini-review series on B cell-directed therapies: 
recent advances in B cell-directed biological therapies for auto-immune disorders. 
Clin Exp Immunol. 2009;157:198–208. 
 
31. Reth, M. & Wienands, J. Initiation and processing of signals from the B cell 
antigen receptor. Annu. Rev. Immunol. 1997;15:453–479. 
 
32. Tolar, P., Sohn, H. W. & Pierce, S. K. The initiation of antigen-induced B cell 
antigen receptor signaling viewed in living cells by fluorescence resonance energy 
transfer. Nature Immunol. 2005;6:1168–1176. 
 
57 
 
33. Vascotto F, Lankar D, Faure-André G, Vargas P, Diaz J, Le Roux D, Yuseff MI, 
Sibarita JB, Boes M, Raposo G, Mougneau E, Glaichenhaus N, Bonnerot C, 
Manoury B, Lennon-Duménil AM. The actin-based motor protein myosin II 
regulates MHC class II trafficking and BCR-driven antigen presentation. J Cell Biol. 
2007;176(7):1007-19. 
 
34. Pillai, S., Cariappa, A. and Moran, S., T. Positive selection and lineage 
commintment during peripheral B-lymphocyte development. Imm. Rev. 2004; 
197: 206-218 
 
35. Lankar, D., Vincent-Schneider, H., Briken, V., Yokozeki, T., Raposo, G., and 
Bonnerot, C. Dynamics of Major Histocompatibility Complex Class II 
Compartments during B Cell Receptor–mediated Cell Activation. J. Exp. Med. 
2002;195 :461-472 
 
36. Vaughan AT, Roghanian A, Cragg MS. B cells—Masters of the immunoverse. 
Int J Biochem Cell Biol. 2011;43:280-5 
 
37. Liu, X., Zhan, Z., Li, D., Xu, L., Ma, F., Zhang, P., Yao, H., and Cao, X. 
Intracellular MHC class II molecules promote TLR-triggered innate immune 
responses by maintaining activation of the kinase Btk. Nat. Immu. 2011;12;5. 
 
38. Palm, N.W. & R. Medzhitov. Pattern recognition receptors and control of 
adaptive immunity. Immunol. Rev. 2009;227:221–233. 
 
39. Uematsu, S. & S. Akira. Toll-Like receptors (TLRs) and their ligands. Handbook 
of Exp. Pharm. 2008:1–20. 
 
58 
 
40. Crampton SP, Voynova E, Bolland S. Innate pathways to B-cell activation and 
tolerance. Ann N Y Acad Sci. 2010;1183:58-68. 
 
41. Glaum, M.C. et al. Toll-like receptor 7-induced naive human B-cell 
differentiation and immunoglobulin production. J. Allergy Clin. 
Immunol.2009;123:224–230. 
 
42. Zhou Z, Hoebe K, Du X, Jiang Z, Shamel L, Beutler B. Antagonism between 
MyD88- and TRIF-dependent signals in B7RP-1 up-regulation. Eur J Immunol. 
2005;35(6):1918-27. 
 
43. Good,K.L., D.T.Avery and S.G. Tangye. Resting human memory B cells are 
intrinsically programmed for enhanced survival and responsiveness to diverse 
stimuli compared to naive B cells.  J. Immuno. 2009;182: 890–901. 
 
44. Pereira, J. P., R. Girard, R. Chaby, A. Cumano, and P. Vieira. Monoallelic 
expression of the murine gene encoding Toll-like receptor 4. Nat. Immunol. 
2003;4: 464–470. 
 
45. Nagai, Y., K. P. Garrett, S. Ohta, U. Bahrun, T. Kouro, S. Akira, K. Takatsu, and 
P. W. Kincade. Toll-like receptors on hematopoietic progenitor cells stimulate 
innate immune system replenishment. Immunity. 2006;24: 801–812. 
 
46. Hayashi, E. A., S.Akira, and A. Nobrega. Role of TLR in B cell development: 
signaling through TLR4 promotes B cell maturation and is inhibited by TLR2. J. 
Immunol. 2005;174: 6639–6647. 
 
59 
 
47. Munroe ME. Functional roles for T cell CD40 in infection and auto-immune 
disease: the role of CD40 in lymphocyte homeostasis. Semin Immunol. 
2009;21:283–288. 
 
48. Hassan GS, Merhi Y, Mourad WM. CD154 and its receptors in inflammatory 
vascular pathologies. Trends Immunol. 2009;30:165–172. 
 
49. Néron S, Nadeau PJ, Darveau A, Leblanc JF. Tuning of CD40–CD154 
Interactions in Human B-Lymphocyte Activation: A Broad Array of In Vitro Models 
for a Complex In Vivo Situation. Arch Immunol Ther Exp. 2011;59(1):25-40 
 
50. Fiorentino, D.F., M.W. Bond, and T.R. Mosmann. Two types of mouse T helper 
cell IV Th2 clones secrete a factor that inhibits cytokine production by Thl clones. 
J. Exp Med. 1989;170:2081.  
 
51. Wolk K, Kunz S, Asadullah K, Sabat R. Cutting edge: immune cells as sources 
and targets of the IL-10 family members? J Immunol. 2002;168: 5397–402. 
 
52. deWaal Malefyt R, Haanen J, Spits H, Roncarolo M-G, te Velde A, Figdor C, 
Johnson K, Kastelein R, Yssel H, de Vries JE. IL-10 and viral IL-10 strongly reduce 
antigen-specific human T cell proliferation by diminishing the antigen-presenting 
capacity of monocytes via downregulation of class II MHC expression. J. Exp. Med. 
1991;174:915–24 
 
53. Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, Moore KW, 
O’Garra A. IL-10 acts on the antigen presenting cell to inhibit cytokine production 
by Th1 cells. J. Immunol. 1991;146:3444–51 
 
60 
 
54. Jung M, Sabat R, Kratzschmar J, Seidel H, Wolk K, Schonbein C, et al. 
Expression profiling of IL-10-regulated genes in human monocytes and peripheral 
blood mononuclear cells from psoriatic patients during IL-10 therapy. Eur J 
Immunol. 2004;34:481–93. 
 
55. Levy Y, Brouet JC. Interleukin-10 prevents spontaneous death of germinal 
center B cells by induction of the bcl-2 protein. J. Clin. Invest. 1994;93:424–28. 
 
56. Cohen SB, Crawley JB, Kahan MC, Feldmann M, Foxwell BM. Interleukin-10 
rescues Tcells from apoptotic cell death: association with an upregulation of Bcl-
2. Immunology. 1997;92: 1–5 
 
57. Fluckiger AC, Durand I, Banchereau J. Interleukin 10 induces apoptotic cell 
death of B-chronic lymphocytic leukemia cells. J. Exp. Med. 1994;179:91–99 
 
58. Go NF, Castle BE, Barrett R, Kastelein R, Dang W, Mosmann TR, Moore KW, 
Howard M. Interleukin 10, a novel B cell stimulatory factor: unresponsiveness of X 
chromosome-linked immunodeficiency B cells. J Exp Med. 1990;172(6):1625-31. 
 
59. Mosser DM, Zhang X. Biology of interleukin-10. Immunol Rev. 2008;226:205-18  
 
60. Amadou,C., A.Kumanovics, E.P.Jones, D.Lambracht-Washington, M.Yoshino,  
and K.F.Lindahl. The mouse major histocompatibility complex: some assembly 
 required. Immunol.Rev. 1999;167:211-221. 
 
61. Klein,J. and A.Sato. The HLA system. First of two parts. N.Engl.J.Med. 
 2000;343:702-709. 
 
61 
 
62. York,I.A. and K.L.Rock. Antigen processing and presentation by the class I 
major histocompatibility complex. Annu.Rev.Immunol. 1996;14:369-396. 
 
63. Klein,J. and A.Sato. 2000. The HLA system. First of two parts. N.Engl.J.Med. 
2000;343:702-709. 
 
64. Steimle,V., C.-A.Siegrist, A.Mottet, B.Lisowska-Grospierre, and B.Mach. 
Regulation of MHC class II expression by interferon-gamma mediated by the 
transactivator gene CIITA. Science. 1994;265:106-109. 
 
65. Servenius,B., L.Rask, and P.A.Peterson. Class II genes of the human major 
histocompatibility complex. The DO beta gene is a divergent member of the class 
II beta gene family. J.Biol.Chem. 1987;262:8759-8766. 
 
66. Denzin,L.K. and P.Cresswell. HLA-DM induces CLIP dissociation from MHC 
class II dimers and facilitates peptide loading. Cell. 1995;82:155-165. 
 
67. Van Ham,S.M., U.Grueneberg, G.Malcherek, I.Broeker, A.Melms, and 
J.Trowsdale. Human histocompatibility leukocyte antigen (HLA)-DM edits 
peptides presented by HLA-DR according to their ligand binding motifs. 
J.Exp.Med. 1996;184:2019-2024. 
 
68. Sherman,M.A., D.A.Weber, and P.E.Jensen. DM enhances peptide binding to 
class II MHC by release of invariant chain-derived peptide. Immunity.1995;3:197-
205. 
 
62 
 
69. Denzin,L.K., D.B.Sant'Angelo, C.Hammond, M.J.Surman, and P.Cresswell. 
Negative regulation by HLA-DO of MHC Class II-restricted antigen processing. 
Science. 1997;278:106-109. 
 
70. van Ham,M., M.van Lith, B.Lillemeier, E.Tjin, U.Gruneberg, D.Rahman, 
L.Pastoors, K.van Meijgaarden, C.Roucard, J.Trowsdale, T.Ottenhoff, D.Pappin, 
and J.Neefjes. Modulation of the major histocompatibility complex class II-
associated peptide repertoire by human histocompatibility leukocyte antigen 
(HLA)-DO. J.Exp.Med. 2000;191:1127-1136. 
 
71. Brown,J.H., T.S.Jardetzky, J.C.Gorga, L.J.Stern, R.G.Urban, J.L.Strominger, and 
D.C.Wiley. Three-dimensional structure of the human class II histocompatibility 
antigen HLA-DR1. Nature. 1993;364:33-39. 
 
72. Rudensky,A.Y., P.Preston-Hurlburt, S.C.Hong, A.Barlow, and C.A.Janeway, Jr. 
Sequence analysis of peptides bound to MHC class II molecules. Nature. 
1991;353:622-627. 
 
73. Chicz,R.M., R.G.Urban, W.S.Lane, J.C.Gorga, L.J.Stern, D.A.A.Vignali, and 
J.L.Strominger. Predominant naturally processed peptides bound to HLA-DR1 are 
derived from MHC-related molecules and are heterogenous in size. Nature. 
1992;358:764-768. 
 
74. Brown,J.H., T.Jardetzky, M.A.Saper, B.Samraoui, P.J.Bjorkman, and D.C.Wiley. 
A hypothetical model of the foreign antigen binding site of class II 
histocompatibility molecules. Nature. 1988;332:845-850. 
 
63 
 
75. Cammarota,G., A.Scheirle, B.Takacs, D.M.Doran, R.Knorr, W.Bannwarth, 
J.Guardiola, and F.Sinigaglia. Identification of a CD4 binding site on the b2 domain 
of HLA- DR molecules. Nature. 1992;356:799-801. 
 
76. Harton,J.A., A.E.Van Hagen, and G.A.Bishop. The cytoplasmic and 
transmembrane domains of MHC class II beta chains deliver distinct signals 
required for MHC class II-mediated B cell activation. Immunity. 1995;3:349-358. 
 
77. Brunet,A., A.Samaan, F.Deshaies, T.J.Kindt, and J.Thibodeau. Functional 
characterization of a lysosomal sorting motif in the cytoplasmic tail of HLA-
DObeta. J.Biol.Chem. 2000;275:37062-37071. 
 
78. Copier,J., M.J.Kleijmeer, S.Ponnambalam, V.Oorschot, P.Potter, J.Trowsdale, 
and A.Kelly. Targeting signal and subcellular compartments involved in the 
intracellular trafficking of HLA-DMB. J.Immunol. 1996;157:1017-1027. 
 
79. Zhong,G., P.Romagnoli, and R.N.Germain. Related leucine-based cytoplasmic 
targeting signals in invariant chain and major histocompatibility complex class II 
molecules control endocytic presentation of distinct determinants in a single 
protein. J.Exp.Med. 1997;185:429-438. 
 
80. El Fakhry,Y., M.Bouillon, C.Leveille, A.Brunet, H.Khalil, J.Thibodeau, and 
W.Mourad. Delineation of the HLA-DR region and the residues involved in the 
association with the cytoskeleton. J.Biol.Chem. 2004;279:18472-18480. 
 
81. Wade,W.F., Z.Z.Chen, R.Maki, S.McKercher, E.Palmer, J.C.Cambier, and 
J.H.Freed. Altered I-A protein-mediated transmembrane signaling in B cells that 
express truncated I-Ak protein. Proc.Natl.Acad.Sci.U.S A. 1989; 86:6297-6301. 
64 
 
 
82. Smiley,S.T., T.M.Laufer, D.Lo, L.H.Glimcher, and M.J.Grusby. Transgenic mice 
expressing MHC class II molecules with truncated Ab cytoplasmic domains reveal 
signaling-independent defects in antigen presentation. Int.Immunol. 1995;7:665-
677. 
 
83. Ohmura-Hoshino M, Matsuki Y, Aoki M, Goto E, Mito M, Uematsu M, Kakiuchi 
T, Hotta H, Ishido S . Inhibition of MHC Class II Expression and Immune Responses 
by c-MIR. J Immunol. 2006;1;177(1):341-54. 
 
84. Hershko, A., and A. Ciechanover. The ubiquitin system. Annu. Rev. Biochem. 
1998;67:425–479. 
 
85. Hewitt, E. W., L. Duncan, D. Mufti, J. Baker, P. G. Stevenson, and P. J. Lehner. 
Ubiquitylation of MHC class I by the K3 viral protein signals internalization and 
TSG101-dependent degradation. EMBO J. 2002;21:2418–2429. 
 
86. Laney JD, Hochstrasser M: Substrate targeting in the ubiquitin system. Cell 
1999;97:427-430. 
 
87. Cadwell, K. and L. Coscoy, Ubiquitination on nonlysine residues by a viral E3 
ubiquitin ligase. Science. 2005;309:5731:127-30. 
 
88. Wang, X., Herr, R. A., Chua, W. J., Lybarger, L., Wiertz, E. J. & Hansen, T. H. 
Ubiquitination of serine, threonine, or lysine residues on the cytoplasmic tail can 
induce ERAD of MHC-I by viral E3 ligase mK3. J. Cell Biol. 2007;177: 613-624. 
 
65 
 
89. Chen, Z. J. Ubiquitin signaling in the NF-κB pathway. Nature Cell Biol. 
2005;7:758–765. 
 
90. Jabbour M, Campbell EM, Fares H, Lybarger L. Discrete domains of MARCH1 
mediate its localization, functional interactions, and posttranscriptional control of 
expression. J Immunol. 2009;183(10):6500-12. 
 
91. Joazeiro, C. A. & Hunter, T. Biochemistry. Ubiquitination--more than two to 
tango. Science. 2000;289:2061 -2062. 
 
92. Ohmura-Hoshino, M., et al., A novel family of membrane-bound E3 ubiquitin 
ligases. J Biochem, 2006;140(2):147-54. 
 
93. Ardley, H. C. & Robinson, P. A. E3 ubiquitin ligases. Essays Biochem. 2005;41, 
15-30. 
 
94. Matsuki, Y., Ohmura-Hoshino, M., Goto, E., Aoki, M., Mito-Yoshida, M., 
Uematsu, M., Hasegawa, T., Koseki, H., Ohara, O., Nakayama, M., Toyooka, K., 
Matsuoka, K., Hotta, H., Yamamoto, A. & Ishido, S. Novel regulation of MHC class 
II function in B cells. EMBO J. 2007;26, 846-854. 
 
95. Shin, J. S., Ebersold, M., Pypaert, M., Delamarre, L., Hartley, A. & Mellman, I. 
Surface expression of MHC class II in dendritic cells is controlled by regulated 
ubiquitination. Nature. 2006;444, 115-118. 
 
96. Ohmura-Hoshino, M., Matsuki, Y., Aoki, M., Goto, E., Mito, M., Uematsu, M., 
Kakiuchi, T., Hotta, H. & Ishido, S. Inhibition of MHC class II expression and 
immune responses by c-MIR. J. Immunol. 2006;177, 341-354. 
66 
 
 
97. Bartee, E., Mansouri, M., Hovey Nerenberg, B. T., Gouveia, K. & Fruh, K. 
Downregulation of major histocompatibility complex class I by human ubiquitin 
ligases related to viral immune evasion proteins. J. Virol. 2004;78, 1109-1120. 
 
98. Thibodeau, J., Bourgeois-Daigneault, MC. H. G. T. J. A. A., Houde, M. B. E. B. A. 
G. ME. d. A. G. E., Baril, M. C. M. & Bontron, S. F. K. L. D. S. V. Interleukin-10-
induced MARCH1 mediates intracellular sequestration of MHC class II in 
monocytes. Eur J Immunol. 2008 May;38(5):1225-30. 
 
99. Naldini L, Blömer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D. 
In vivo gene delivery and stable transduction of nondividing cells by a lentiviral 
vector. Science. 1996 ;12;272:263-7. 
 
100. Blömer U., Naldini L., Kafri T., Trono D., Verma I. M., and Gage F. H. Highly 
efficient and sustained gene transfer in adult neurons with a lentivirus vector. J 
Virol 1997; 71: 6641-6649. 
 
101. Kafri T., Blömer U., Peterson A., Gage F. H. and Verma I. M. Sustained 
expression of genes delivered directly into liver and muscles by lentiviral vectors. 
Nat Genet. 1997;17:314-317 
 
102. Trono D. Lentiviral vectors: turning a deadly foe into a therapeutic agent. 
Gen Ther. 2000;7: 20-23 
 
103. Naldini L, Blömer U, Gage FH, Trono D, Verma IM. Efficient transfer, 
integration, and sustained long-term expression of the transgene in adult rat 
67 
 
brains injected with a lentiviral vector. Proc Natl Acad Sci U S A. 
1996;15;93:11382-8. 
104. Ning Fei Go, Brian E. Castle, Robin Barrett, Robert Kastelein, Warren Dang,- 
Tim R. Mosmann, Kevin W. Moore, and Maureen Howard. Interleukin 10, a Novel 
B Cell Stimulatory Factor: Unresponsiveness of X Chromosome-linked 
Immunodeficiency B Cells. J. Exp. Med. 1990; 172 :1625-1631. 
 
105. Pillai, S., Cariappa, A. and Moran, S., T. Positive selection and lineage 
commintment during peripheral B-lymphocyte development. Imm. Rev. 2004; 
197: 206-218 
 
106. Gerondakis, S., Grumont, R., J. and Banerjee, A. Regulating B-cell activation 
and survival in response to TLR signals. Immu. And Cell Bio. 2007;85:471-475. 
 
107. Liu, X., Zhan, Z., Li, D., Xu, L., Ma, F., Zhang, P., Yao, H., and Cao, X. 
Intracellular MHC class II molecules promote TLR-triggered innate immune 
responses by maintaining activation of the kinase Btk. Nat. Immu. 2011;12;5.  
 
108. Toyomoto M, Ishido S, Miyasaka N, Sugimoto H, Kohsaka H. Anti-arthritic 
effect of E3 ubiquitin ligase, c-MIR, expression in the joints. Int Immunol. 
2011;23:177-83. 
 
 
